NCT04020185: Safety and Efficacy Study of IMSA101 in Refractory Malignancies

NCT04020185
Breast Cancer Type: HER2+, Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1|Ph+ase 2
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with HR++ breast cancer, Patients with known untreated brain metastases or treated brain metastases that are unstable
https://ClinicalTrials.gov/show/NCT04020185

Comments are closed.

Up ↑